Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | PLAT | P00750 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14417956 | 1.00 | CYP2D6 (0.54) | CYP2D6SIGMAR1NCF1PLGPLAT | |
| SCHEMBL19992007 | 1.00 | CYP2D6 (0.54) | CYP2D6SIGMAR1NCF1PLGPLAT | |
| Decarboxylated Derivative SCHEMBL5183307 | 1.00 | CYP2D6 (0.54) | CYP2D6SIGMAR1NCF1PLGPLAT | |
| SCHEMBL15444322 | 1.00 | CYP2D6 (0.54) | CYP2D6SIGMAR1NCF1PLGPLAT | |
| SCHEMBL131302 | 1.00 | CYP2D6 (0.54) | CYP2D6SIGMAR1NCF1PLGPLAT | |
| SCHEMBL17117548 | 1.00 | CYP2D6 (0.54) | CYP2D6SIGMAR1NCF1PLGPLAT | |
| SCHEMBL10990399 | 1.00 | CYP2D6 (0.54) | CYP2D6SIGMAR1NCF1PLGPLAT | |
| SCHEMBL12252084 | 1.00 | CYP2D6 (0.54) | CYP2D6SIGMAR1NCF1PLGPLAT | |
| SCHEMBL22078896 | 1.00 | CYP2D6 (0.54) | CYP2D6SIGMAR1NCF1PLGPLAT | |
| SCHEMBL18102722 | 1.00 | CYP2D6 (0.54) | CYP2D6SIGMAR1NCF1PLGPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024015863-A1 | CBL-B INHIBITOR, COMPOSITIONS COMPRISING A CBL-B INHIBITOR IN A METHOD OF TREATING A DISEASE ASSOCIATED WITH CELL PROLIFERATION | HOTSPOT THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-11834417-B2 | Compositions for the treatment of hypertension and/or fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2023-12-05 | — | — | US | disclosed |
| EP-3830087-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2023-05-24 | — | — | EP | disclosed |
| US-11566025-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-01-31 | — | — | US | disclosed |
| WO-2022114908-A1 | ORAL FORMULATION OF BIOLOGICALLY ACTIVE MATERIAL CONJUGATE HAVING BIOTIN MOIETY, FATTY ACID MOIETY, OR COMBINATION THEREOF COUPLED THERETO | (주)디앤디파마텍 | 2022-06-02 | — | — | WO | disclosed |
| EP-3984997-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Les Laboratoires Servier SAS (FR) | 2022-04-20 | — | — | EP | disclosed |
| US-20210361636-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2021-11-25 | — | — | US | disclosed |
| WO-2021188880-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-11125742-B2 | Non-specific reaction inhibitor, method for inhibiting non-specific reaction, and kit | LSI MEDIENCE CORPORATION (JP) | 2021-09-21 | — | — | US | disclosed |
| US-20210253534-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| US-20120061325-A1 | CHELATING COMPOUNDS AND IMMOBILIZED TETHERED CHELATORS | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2012-03-15 | — | — | US | disclosed |
| US-7687507-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| US-6890929-B2 | Immunosuppressants; lupus, multiple sclerosis, skin disorders, antiarthritic agents, antihistamines, antiulcer agents, Crohn's disease | PFIZER, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1087970-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | PFIZER INC. | 2003-11-13 | — | — | US | disclosed |
| US-6610847-B2 | Tyrosine kinase inhibitors; immunosuppressants | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| EP-1087970-A1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065908-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120061325-A1 | CHELATING COMPOUNDS AND IMMOBILIZED TETHERED CHELATORS | BTD, TTPA, SLC39A7 | CYP2D6 4832/4885SIGMAR1 3790/4885NCF1 737/4885 |
| US-20210361636-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | NAMPT, NME4, ABAT | CYP2D6 3960/4885SIGMAR1 3874/4885NCF1 1742/4885 |
| US-11125742-B2 | Non-specific reaction inhibitor, method for inhibiting non-specific reaction, and kit | KIT, SPR, SHBG | CYP2D6 862/4885SIGMAR1 1343/4885NCF1 893/4885 |
| US-11566025-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | CYP2D6 3515/4885SIGMAR1 3557/4885NCF1 1198/4885 |
| US-20210253534-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, GPBAR1, SLC10A1 | CYP2D6 647/4885SIGMAR1 613/4885NCF1 1648/4885 |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | CYP2D6 1996/4885SIGMAR1 4528/4885NCF1 1894/4885 |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK3, JAK1, JAK2 | CYP2D6 1867/4885SIGMAR1 4492/4885NCF1 2256/4885 |
| US-11834417-B2 | Compositions for the treatment of hypertension and/or fibrosis | TGFB1, REN, TGFB2 | CYP2D6 4711/4885SIGMAR1 3513/4885NCF1 1276/4885 |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | JAK1, JAK3, JAK2 | CYP2D6 1996/4885SIGMAR1 4528/4885NCF1 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.